·制药 ·内部研究
Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade
Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.
Hold
